ロード中...
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
The approval of guselkumab marks the entry of the IL-23 inhibitor class into the therapeutic armamentarium for patients with moderate-to-severe plaque psoriasis. This class specifically targets the upstream portion of the type 17 helper T (Th17) axis, which has been implicated as a key driver of the...
保存先:
| 出版年: | Drug Des Devel Ther |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6587972/ https://ncbi.nlm.nih.gov/pubmed/31354244 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S137588 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|